{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:45:43Z","timestamp":1793857543514,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004817","name":"Lund University Medical Faculty Foundation","doi-asserted-by":"publisher","award":["Lund University Medical Faculty Foundation"],"award-info":[{"award-number":["Lund University Medical Faculty Foundation"]}],"id":[{"id":"10.13039\/501100004817","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003173","name":"Crafoordska Stiftelsen","doi-asserted-by":"publisher","award":["Crafoordska Stiftelsen"],"award-info":[{"award-number":["Crafoordska Stiftelsen"]}],"id":[{"id":"10.13039\/501100003173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006075","name":"Greta och Johan Kocks stiftelser","doi-asserted-by":"publisher","award":["Greta och Johan Kocks stiftelser"],"award-info":[{"award-number":["Greta och Johan Kocks stiftelser"]}],"id":[{"id":"10.13039\/501100006075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","award":["Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond"],"award-info":[{"award-number":["Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","award":["Magnus Bergvalls Stiftelse"],"award-info":[{"award-number":["Magnus Bergvalls Stiftelse"]}],"id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005390","name":"Alfred \u00d6sterlunds Stiftelse","doi-asserted-by":"publisher","award":["Alfred \u00d6sterlunds Stiftelse"],"award-info":[{"award-number":["Alfred \u00d6sterlunds Stiftelse"]}],"id":[{"id":"10.13039\/501100005390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["Vetenskapsr\u00e5det"],"award-info":[{"award-number":["Vetenskapsr\u00e5det"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","award":["Reumatikerf\u00f6rbundet"],"award-info":[{"award-number":["Reumatikerf\u00f6rbundet"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear. Neurofilament light (NfL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal damage in various neurological disorders. In this cross-sectional study, plasma and CSF concentrations of NfL were explored as a marker of neuronal damage in SLE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy-two consecutive SLE out-patients and 26 healthy controls, all female, aged &lt;\u200955\u2009years, underwent magnetic resonance imaging (MRI) and neurocognitive testing. NfL concentrations in plasma from all individuals and in CSF from 32 patients were measured with single-molecule array technology. Patients were assessed by a rheumatologist and neurologist to define neuropsychiatric involvement (NPSLE) according to three attribution models: SLICC A, SLICC B and ACR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma and CSF NfL concentrations correlated strongly (<jats:italic>r<\/jats:italic>\u2009=\u20090.72, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Both NPSLE and non-NPSLE patients in all attribution models had higher plasma NfL concentrations compared with healthy controls (log-NfL, pg\/ml, mean (SD); healthy controls (0.71 (0.17)); SLICC A model: NPSLE (0.87 (0.13), <jats:italic>p<\/jats:italic>\u2009=\u20090.003), non-NPSLE (0.83 (0.18), <jats:italic>p<\/jats:italic>\u2009=\u20090.005); SLICC B model: NPSLE (0.87 (0.14), <jats:italic>p<\/jats:italic>\u2009=\u20090.001), non-NPSLE (0.83 (0.18), <jats:italic>p<\/jats:italic>\u2009=\u20090.008); ACR model: NPSLE (0.86 (0.16), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), non-NPSLE (0.81 (0.17), <jats:italic>p<\/jats:italic>\u2009=\u20090.044)). Plasma and CSF NfL concentrations did not differ between NPSLE and non-NPSLE patients. Higher plasma NfL concentrations correlated with larger CSF volumes on MRI (<jats:italic>r<\/jats:italic>\u2009=\u20090.34, <jats:italic>p<\/jats:italic>\u2009=\u20090.005), and was associated with poorer cognitive performance in the domains of simple attention, psychomotor speed and verbal memory. SLICC\/ACR-Damage Index \u22651 was independently associated with higher plasma NfL concentrations (\u03b2\u2009=\u20090.074, <jats:italic>p<\/jats:italic>\u2009=\u20090.038). Higher plasma creatinine concentrations, anti-dsDNA-positivity, low complement C3 levels, or a history of renal involvement were associated with higher plasma NfL concentrations (\u03b2\u2009=\u20090.003, <jats:italic>p<\/jats:italic>\u2009=\u20090.009; \u03b2\u2009=\u20090.072, <jats:italic>p<\/jats:italic>\u2009=\u20090.031; \u03b2\u2009=\u20090.077, <jats:italic>p<\/jats:italic>\u2009=\u20090.027; \u03b2\u2009=\u20090.069, <jats:italic>p<\/jats:italic>\u2009=\u20090.047, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Higher plasma NfL concentrations in NPSLE and non-NPSLE patients may indicate a higher degree of neuronal damage in SLE in general, corresponding to cognitive impairment and organ damage development. Furthermore, our results may indicate a higher degree of neuronal breakdown in patients with active SLE, also without overt clinical symptoms. NfL may serve as an indicator of neuronal damage in SLE in further studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02998-3","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T07:04:08Z","timestamp":1670569448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-1635","authenticated-orcid":false,"given":"Kristoffer A.","family":"Zervides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Nystedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Gullstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia C.","family":"Sundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders A.","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"J\u00f6nsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"7","key":"2998_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0961203316635288","volume":"25","author":"RF Ingvarsson","year":"2016","unstructured":"Ingvarsson RF, Bengtsson AA, J\u00f6nsen A. Variations in the epidemiology of systemic lupus erythematosus in southern Sweden. Lupus. 2016;25(7):772\u201380.","journal-title":"Lupus"},{"key":"2998_CR2","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"2998_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/rheumatology\/41.11.1308","volume":"41","author":"A J\u00f6nsen","year":"2002","unstructured":"J\u00f6nsen A. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41(11):1308\u201312.","journal-title":"Rheumatology"},{"issue":"1","key":"2998_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/art.22305","volume":"56","author":"JG Hanly","year":"2007","unstructured":"Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265\u201373.","journal-title":"Arthritis Rheum"},{"key":"2998_CR5","first-page":"579","volume-title":"Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Vol. 10, Nature Reviews Neurology","author":"H Jeltsch-David","year":"2014","unstructured":"Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Vol. 10, Nature Reviews Neurology: Nature Publishing Group; 2014. p. 579\u201396."},{"key":"2998_CR6","first-page":"240","volume-title":"What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Vol. 48, Seminars in arthritis and rheumatism","author":"RH Al","year":"2018","unstructured":"Al RH, Tani C, Kwan A, Marzouk S, Colosimo K, Medina-Rosas J, et al. What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis. Vol. 48, Seminars in arthritis and rheumatism: W.B. Saunders; 2018. p. 240\u201355."},{"issue":"6","key":"2998_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/0961203316668417","volume":"26","author":"SJ Wiseman","year":"2017","unstructured":"Wiseman SJ, Bastin ME, Hamilton IF, Hunt D, Ritchie SJ, Amft EN, et al. Fatigue and cognitive function in systemic lupus erythematosus: associations with white matter microstructural damage. A diffusion tensor MRI study and meta-analysis. Lupus. 2017;26(6):588\u201397.","journal-title":"Lupus"},{"issue":"7","key":"2998_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0961203318763533","volume":"27","author":"B Cannerfelt","year":"2018","unstructured":"Cannerfelt B, Nystedt J, J\u00f6nsen A, L\u00e4tt J, van Westen D, Lilja A, et al. White matter lesions and brain atrophy in systemic lupus erythematosus patients: correlation to cognitive dysfunction in a cohort of systemic lupus erythematosus patients using different definition models for neuropsychiatric systemic lupus erythematosus. Lupus. 2018;27(7):1140\u20139.","journal-title":"Lupus"},{"issue":"5","key":"2998_CR9","first-page":"732","volume":"19","author":"JG Hanly","year":"1992","unstructured":"Hanly JG, Walsh NMG, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol. 1992;19(5):732\u201341.","journal-title":"J Rheumatol"},{"key":"2998_CR10","first-page":"527","volume-title":"Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. Vol. 7, International journal of clinical rheumatology","author":"AJ Wilhelm","year":"2012","unstructured":"Wilhelm AJ, Major AS. Accelerated atherosclerosis in systemic lupus erythematosus: mechanisms and prevention approaches. Vol. 7, International journal of clinical rheumatology: NIH Public Access; 2012. p. 527\u201339."},{"key":"2998_CR11","first-page":"1020","volume-title":"Small vessel disease. Vol. 10, frontiers in neurology","author":"AM Hakim","year":"2019","unstructured":"Hakim AM. Small vessel disease. Vol. 10, frontiers in neurology: Frontiers Media S.A; 2019. p. 1020."},{"key":"2998_CR12","first-page":"577","volume-title":"Neurofilaments as biomarkers in neurological disorders. Vol. 14, nature reviews neurology","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Vol. 14, nature reviews neurology: Nature Publishing Group; 2018. p. 577\u201389."},{"key":"2998_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2016","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the Neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135\u201340.","journal-title":"EBioMedicine"},{"issue":"6","key":"2998_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Sch\u00e4delin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370.","journal-title":"Ann Neurol"},{"key":"2998_CR15","first-page":"761","volume-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Vol. 17, expert review of molecular diagnostics","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Vol. 17, expert review of molecular diagnostics: Taylor and Francis Ltd; 2017. p. 761\u201370."},{"key":"2998_CR16","volume-title":"Neurofilament light chain as a biomarker in neurological disorders. Vol. 90, journal of neurology, neurosurgery and psychiatry","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Vol. 90, journal of neurology, neurosurgery and psychiatry: BMJ Publishing Group; 2019."},{"issue":"10","key":"2998_CR17","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/art.11279","volume":"48","author":"E Trysberg","year":"2003","unstructured":"Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48(10):2881\u20137.","journal-title":"Arthritis Rheum"},{"key":"2998_CR18","doi-asserted-by":"crossref","unstructured":"Tjensvoll AB, Lauvsnes MB, Zetterberg H, Kval\u00f8y JT, Kvivik I, Maroni SS, et al. Neurofilament light is a biomarker of brain involvement in lupus and primary Sj\u00f6gren\u2019s syndrome.\u00a0J Neurol. 2021;268(4):1385.","DOI":"10.1007\/s00415-020-10290-y"},{"key":"2998_CR19","first-page":"1","volume":"1","author":"MB Lauvsnes","year":"2021","unstructured":"Lauvsnes MB, Zetterberg H, Blennow K, Kval\u00f8y JT, Tjensvoll AB, Maroni S, et al. Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus. J Neurol. 2021;1:1\u201311.","journal-title":"J Neurol"},{"key":"2998_CR20","doi-asserted-by":"publisher","first-page":"175628642110514","DOI":"10.1177\/17562864211051497","volume":"14","author":"S Engel","year":"2021","unstructured":"Engel S, Boedecker S, Marczynski P, Bittner S, Steffen F, Weinmann A, et al. Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus. Ther Adv Neurol Disord. 2021;14:175628642110514.","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"2998_CR21","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f5n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2998_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.acn.2006.05.007","volume":"21","author":"CT Gualtieri","year":"2006","unstructured":"Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, CNS vital signs. Arch Clin Neuropsychol. 2006;21(7):623\u201343.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"2998_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s41927-022-00253-3","volume":"6","author":"L Langensee","year":"2022","unstructured":"Langensee L, M\u00e5rtensson J, J\u00f6nsen A, Zervides K, Bengtsson A, Nystedt J, et al. Cognitive performance in systemic lupus erythematosus patients: a cross-sectional and longitudinal study. BMC Rheumatol. 2022;6(1):22.","journal-title":"BMC Rheumatol"},{"issue":"3","key":"2998_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363\u20139.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2998_CR25","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowltz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"4","key":"2998_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","volume":"42","author":"MH Liang","year":"1999","unstructured":"Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599\u2013608.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2998_CR27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.57.3.496","volume":"57","author":"H Ainiala","year":"2001","unstructured":"Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57(3):496\u2013500.","journal-title":"Neurology"},{"issue":"5","key":"2998_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X","volume":"45","author":"H Ainiala","year":"2001","unstructured":"Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Mets\u00e4noja R, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45(5):419\u201323.","journal-title":"Arthritis Rheum"},{"issue":"19","key":"2998_CR29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"1","key":"2998_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1191\/096120399678847344","volume":"8","author":"MG Sabbadini","year":"1999","unstructured":"Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus. 1999;8(1):11\u20139.","journal-title":"Lupus"},{"issue":"3","key":"2998_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.semarthrit.2013.05.003","volume":"43","author":"EJ Sutton","year":"2013","unstructured":"Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352\u201361.","journal-title":"Semin Arthritis Rheum"},{"key":"2998_CR32","first-page":"1601","volume-title":"The complement system in systemic lupus erythematosus: An update. Vol. 73, annals of the rheumatic diseases","author":"J Leffler","year":"2014","unstructured":"Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: An update. Vol. 73, annals of the rheumatic diseases: BMJ Publishing Group; 2014. p. 1601\u20136."},{"key":"2998_CR33","first-page":"415","volume-title":"Role of interferons in SLE. Vol. 31, best practice and research: clinical rheumatology","author":"AA Bengtsson","year":"2017","unstructured":"Bengtsson AA, R\u00f6nnblom L. Role of interferons in SLE. Vol. 31, best practice and research: clinical rheumatology: Bailliere Tindall Ltd; 2017. p. 415\u201328."},{"key":"2998_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10:1 2020 Nov 23;10(1):1\u20137.","journal-title":"Sci Rep"},{"issue":"1","key":"2998_CR35","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/lupus-2020-000398","volume":"7","author":"O Nived","year":"2020","unstructured":"Nived O, Ingvarsson RF, J\u00f6ud A, Linge P, Tyd\u00e9n H, J\u00f6nsen A, et al. Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus Sci Med. 2020;7(1):e000398.","journal-title":"Lupus Sci Med"},{"issue":"4","key":"2998_CR36","doi-asserted-by":"publisher","first-page":"e0174572","DOI":"10.1371\/journal.pone.0174572","volume":"12","author":"JT Gustafsson","year":"2017","unstructured":"Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, \u00d6hrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus,-a matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS One. 2017;12(4):e0174572.","journal-title":"PLoS One"},{"issue":"20","key":"2998_CR37","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.0000000000004645","volume":"89","author":"T Gattringer","year":"2017","unstructured":"Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017;89(20):2108\u201314.","journal-title":"Neurology"},{"key":"2998_CR38","first-page":"97","volume-title":"Neuroprotective versus Neuroinflammatory roles of complement: from development to disease. Vol. 44, trends in neurosciences","author":"M Kanmogne","year":"2021","unstructured":"Kanmogne M, Klein RS. Neuroprotective versus Neuroinflammatory roles of complement: from development to disease. Vol. 44, trends in neurosciences: Elsevier Ltd; 2021. p. 97\u2013109."},{"key":"2998_CR39","doi-asserted-by":"crossref","unstructured":"Donnellan C, Cohen H, Werring DJ. Cognitive dysfunction and associated neuroimaging biomarkers in antiphospholipid syndrome: a systematic review.\u00a0Rheumatology (Oxford). 2022;61(1):24.","DOI":"10.1093\/rheumatology\/keab452"},{"issue":"9","key":"2998_CR40","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/diagnostics10090720","volume":"10","author":"LA Dobrynina","year":"2020","unstructured":"Dobrynina LA, Sh Gadzhieva Z, Shamtieva KV, Kremneva EI, Akhmetzyanov BM, Kalashnikova LA, et al. Microstructural predictors of cognitive impairment in cerebral small vessel disease and the conditions of their formation. Diagnostics. 2020;10(9):720.","journal-title":"Diagnostics"},{"issue":"Suppl 2","key":"2998_CR41","first-page":"A29","volume":"9","author":"KA Zervides","year":"2022","unstructured":"Zervides KA, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren PC, et al. PO.1.13\u00a0Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Lupus Sci Med. 2022;9(Suppl 2):A29.","journal-title":"Lupus Sci Med"},{"issue":"Suppl 1","key":"2998_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/annrheumdis-2022-eular.2605","volume":"81","author":"K Zervides","year":"2022","unstructured":"Zervides K, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren P, et al. POS0116\u00a0Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus erythematosus. Ann Rheum Dis. 2022;81(Suppl 1):283.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02998-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T07:07:53Z","timestamp":1670569673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02998-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2998"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02998-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained ethics approval by the Lund Regional Ethics Board diary numbers 2012\/254 & 2012\/677 (on January 1st 2019 the six Swedish regional boards were combined into one authority, the Swedish Ethical Review Authority). The study was conducted in compliance with the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2\u2009years, he has received consultancy\/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. AJ has received consultancy fees from GlaxoSmithKline and Astra Zeneca. The other authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"467"}}